Clinical Trial Update: A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies [Phase 1]

View source ↗

Summary

Pfizer's Phase 1 trial of PF-08046037 alone or with sasanlimab in advanced cancers has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Malignant Melanoma
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• PF-08046037
• Sasanlimab (sasanlimab)

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal | Phase 1 | Status: TERMINATED